ImageneBio (NASDAQ:IMA) Shares Up 2.4% – Still a Buy?

ImageneBio, Inc. (NASDAQ:IMA) shares traded up 2.4% on Thursday . The stock traded as high as $7.09 and last traded at $6.70. 88,116 shares traded hands during trading, an increase of 111% from the average session volume of 41,829 shares. The stock had previously closed at $6.54.

Analyst Ratings Changes

IMA has been the topic of several recent research reports. Leerink Partners assumed coverage on ImageneBio in a research report on Friday, October 24th. They issued an “outperform” rating and a $30.00 price target on the stock. Wall Street Zen downgraded ImageneBio from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Finally, Wedbush cut ImageneBio from a “neutral” rating to an “underperform” rating in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $26.50.

ImageneBio Stock Performance

The stock’s fifty day moving average price is $6.73 and its 200-day moving average price is $8.52. The firm has a market cap of $74.91 million, a PE ratio of -0.83 and a beta of 0.43.

Insider Transactions at ImageneBio

In related news, Director Joseph P. Slattery bought 16,000 shares of the company’s stock in a transaction on Wednesday, December 24th. The stock was bought at an average cost of $5.99 per share, with a total value of $95,840.00. Following the completion of the acquisition, the director owned 16,000 shares in the company, valued at approximately $95,840. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 5.94% of the company’s stock.

Institutional Investors Weigh In On ImageneBio

A number of institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC raised its holdings in ImageneBio by 170.8% during the fourth quarter. Barclays PLC now owns 10,797 shares of the company’s stock worth $74,000 after purchasing an additional 6,810 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in ImageneBio in the fourth quarter valued at $76,000. Millennium Management LLC purchased a new position in shares of ImageneBio in the fourth quarter valued at $79,000. Bridgeway Capital Management LLC acquired a new position in shares of ImageneBio during the 3rd quarter worth $104,000. Finally, NewEdge Advisors LLC acquired a new position in shares of ImageneBio during the 3rd quarter worth $106,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.